[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity

Artiva Biotherapeutics, Inc. President and CEO, who also serves as a director, reported an equity compensation change effective December 12, 2025.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. President and CEO, who also serves as a director, reported an equity compensation change effective December 12, 2025. The company cancelled several employee stock options listed in the filing, with exercise prices ranging from $5.01 to $13.47 per share, covering multiple grants that were scheduled to vest over multi-year periods.

In exchange for the cancelled options, the reporting person received 869,136 restricted stock units under the company’s 2024 Equity Incentive Plan, recorded at a price of $0 per unit. Following this option-for-RSU exchange, the reporting person beneficially owned 1,213,135 shares of the company’s common stock, held directly.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Aslan Fred

Role President and CEO

Type	Security	Shares	Price	Value
Disposition	Employee Stock Option (Right to Buy)	100,577	$0.00	$0.00
Disposition	Employee Stock Option (Right to Buy)	51,463	$0.00	$0.00
Disposition	Employee Stock Option (Right to Buy)	257,319	$0.00	$0.00
Disposition	Employee Stock Option (Right to Buy)	26,450	$0.00	$0.00
Disposition	Employee Stock Option (Right to Buy)	113,999	$0.00	$0.00
Disposition	Employee Stock Option (Right to Buy)	319,331	$0.00	$0.00
Grant/Award	Common Stock	869,136	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 1,213,135 shares (Direct)

Footnotes (6)

1. F1. Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").
2. F2. On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
3. F3. 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
4. F4. 25% of the shares vest on January 1, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
5. F5. Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.
6. F6. 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/12/2025 - 07:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aslan Fred

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		869,136(1)	A	$0(2)	1,213,135	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$5.01	12/12/2025		D			100,577	(3)	02/23/2031	Common Stock	100,577	(2)	0	D
Employee Stock Option (Right to Buy)	$5.01	12/12/2025		D			51,463	(3)	12/17/2030	Common Stock	51,463	(2)	0	D
Employee Stock Option (Right to Buy)	$5.01	12/12/2025		D			257,319	(4)	12/17/2030	Common Stock	257,319	(2)	0	D
Employee Stock Option (Right to Buy)	$5.18	12/12/2025		D			26,450	(5)	01/23/2034	Common Stock	26,450	(2)	0	D
Employee Stock Option (Right to Buy)	$13.47	12/12/2025		D			113,999	(6)	05/01/2034	Common Stock	113,999	(2)	0	D
Employee Stock Option (Right to Buy)	$12	12/12/2025		D			319,331	(6)	07/17/2034	Common Stock	319,331	(2)	0	D

Explanation of Responses:

1. Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").

2. On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.

3. 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.

4. 25% of the shares vest on January 1, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.

5. Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.

6. 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Andrew Cronauer, Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.